Kenneth Pittman
Long only, value, biotech, healthcare

Cytokinetics Has Potential Positive Catalysts, But Concerning Technical Picture

Quick Background:

In May, I wrote an article on Cytokinetics (NASDAQ:CYTK) detailing why it still shows value potential despite setbacks. I have now been following Cytokinetics for over a year and a half, monitoring both clinical developments and the technical picture. I am a physician (board certified in Child Psychiatry, Psychiatry, and Pediatrics) and familiar with medical literature.

Today, I am writing to update Cytokinetics' progress with both additional clinical data as well as the technical performance of the stock.

Additional Data on Tirasemtiv

Cytokinetics has released several sets of additional pre-defined data sets on June 2nd, June 13th, and July 10th.

June 2nd Data

The headline to the June 2nd data was that the positive effects of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details